



REPORTED SALES vs. PRIOR PERIOD (\$MM)

FIRST QUARTER

CONSUMER SEGMENT <sup>(2)</sup>

SKIN CARE

	2009	2008	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
US	423	382	10.7%	10.7%	-
Intl	419	458	-8.5%	5.4%	-13.9%
WW	842	840	0.2%	7.8%	-7.6%

BABY CARE

US	102	115	-11.3%	-11.3%	-
Intl	387	418	-7.4%	4.3%	-11.7%
WW	489	533	-8.3%	0.9%	-9.2%

ORAL CARE

US	188	199	-5.5%	-5.5%	-
Intl	177	187	-5.3%	11.6%	-16.9%
WW	365	386	-5.4%	2.8%	-8.2%

OTC/NUTRITIONALS

US	726	842	-13.8%	-13.8%	-
Intl	622	752	-17.3%	-2.4%	-14.9%
WW	1,348	1,594	-15.4%	-8.4%	-7.0%

WOMEN'S HEALTH

US	149	148	0.7%	0.7%	-
Intl	274	313	-12.5%	0.5%	-13.0%
WW	423	461	-8.2%	0.7%	-8.9%

WOUND CARE / OTHER

US	138	133	3.8%	3.8%	-
Intl	106	117	-9.4%	4.2%	-13.6%
WW	244	250	-2.4%	4.0%	-6.4%

TOTAL CONSUMER

US	1,726	1,819	-5.1%	-5.1%	-
Intl	1,985	2,245	-11.6%	2.4%	-14.0%
WW	3,711	4,064	-8.7%	-1.0%	-7.7%

\* See footnotes on page 3



REPORTED SALES vs. PRIOR PERIOD (\$MM)

FIRST QUARTER

	2009	2008	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
<b>PHARMACEUTICAL SEGMENT <sup>(2)</sup></b>					
<b>ACIPHEX/PARIET</b>					
US	138	116	19.0%	19.0%	-
Intl	125	161	-22.4%	-8.4%	-14.0%
WW	263	277	-5.1%	3.0%	-8.1%
<b>CONCERTA</b>					
US	269	224	20.1%	20.1%	-
Intl	75	66	13.6%	37.0%	-23.4%
WW	344	290	18.6%	23.9%	-5.3%
<b>DURAGESIC/FENTANYL TRANSDERMAL</b>					
US	75	75	0.0%	0.0%	-
Intl	156	158	-1.3%	12.6%	-13.9%
WW	231	233	-0.9%	8.5%	-9.4%
<b>LEVAQUIN/FLOXIN</b>					
US	408	474	-13.9%	-13.9%	-
Intl	17	22	-22.7%	-3.1%	-19.6%
WW	425	496	-14.3%	-13.4%	-0.9%
<b>PROCRIT/EPREX</b>					
US	321	334	-3.9%	-3.9%	-
Intl	229	295	-22.4%	-10.0%	-12.4%
WW	550	629	-12.6%	-6.8%	-5.8%
<b>RAZADYNE/REMINYL</b>					
US	13	50	-74.0%	-74.0%	-
Intl	88	99	-11.1%	5.1%	-16.2%
WW	101	149	-32.2%	-21.5%	-10.7%
<b>REMICADE</b>					
US	737	676	9.0%	9.0%	-
US Exports <sup>(4)</sup>	286	320	-10.6%	-10.6%	-
Intl	5	2	150.0%	139.3%	10.7%
WW	1,028	998	3.0%	3.0%	-
<b>RISPERDAL/RISPERIDONE</b>					
US	118	582	-79.7%	-79.7%	-
Intl	157	227	-30.8%	-24.6%	-6.2%
WW	275	809	-66.0%	-64.2%	-1.8%
<b>RISPERDAL CONSTA</b>					
US	126	101	24.8%	24.8%	-
Intl	199	208	-4.3%	13.9%	-18.2%
WW	325	309	5.2%	17.5%	-12.3%
<b>TOPAMAX</b>					
US	495	520	-4.8%	-4.8%	-
Intl	107	126	-15.1%	0.1%	-15.2%
WW	602	646	-6.8%	-3.8%	-3.0%
<b>VELCADE</b>					
US	-	2	-100.0%	-100.0%	-
Intl	192	182	5.5%	21.8%	-16.3%
WW	192	184	4.3%	20.5%	-16.2%
<b>OTHER</b>					
US	688	596	15.4%	15.4%	-
Intl	756	813	-7.0%	9.1%	-16.1%
WW	1,444	1,409	2.5%	11.8%	-9.3%
<b>TOTAL PHARMACEUTICAL</b>					
US	3,674	4,070	-9.7%	-9.7%	-
Intl	2,106	2,359	-10.7%	2.8%	-13.5%
WW	5,780	6,429	-10.1%	-5.1%	-5.0%

**MAJOR NEW PHARMACEUTICAL PRODUCTS <sup>(5)</sup>**

<b>PREZISTA</b>					
US	72	32	125.0%	125.0%	-
Intl	50	42	19.0%	41.1%	-22.1%
WW	122	74	64.9%	77.3%	-12.4%
<b>INVEGA</b>					
US	66	57	15.8%	15.8%	-
Intl	25	9	177.8%	221.8%	-44.0%
WW	91	66	37.9%	43.8%	-5.9%

\* See footnotes on page 3

**REPORTED SALES vs. PRIOR PERIOD (\$MM)**

**FIRST QUARTER**

**MEDICAL DEVICES AND DIAGNOSTICS** <sup>(2) (3)</sup>

CORDIS <sup>(6)</sup>

	2009	2008	% Change		
			Reported	Operational <sup>(1)</sup>	Currency
US	246	342	-28.1%	-28.1%	-
Intl	422	459	-8.1%	-1.7%	-6.4%
WW	668	801	-16.6%	-12.9%	-3.7%

DEPUY

US	766	709	8.0%	8.0%	-
Intl	526	578	-9.0%	6.4%	-15.4%
WW	1,292	1,287	0.4%	7.3%	-6.9%

DIABETES CARE

US	270	303	-10.9%	-10.9%	-
Intl	271	312	-13.1%	-1.3%	-11.8%
WW	541	615	-12.0%	-6.0%	-6.0%

ETHICON

US	405	341	18.8%	18.8%	-
Intl	548	604	-9.3%	3.7%	-13.0%
WW	953	945	0.8%	9.1%	-8.3%

ETHICON ENDO-SURGERY

US	454	429	5.8%	5.8%	-
Intl	561	574	-2.3%	11.4%	-13.7%
WW	1,015	1,003	1.2%	8.6%	-7.4%

ORTHO-CLINICAL DIAGNOSTICS

US	277	238	16.4%	16.4%	-
Intl	190	205	-7.3%	3.2%	-10.5%
WW	467	443	5.4%	10.3%	-4.9%

VISION CARE

US	234	226	3.5%	3.5%	-
Intl	365	381	-4.2%	-1.1%	-3.1%
WW	599	607	-1.3%	0.6%	-1.9%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS

US	2,652	2,588	2.5%	2.5%	-
Intl	2,883	3,113	-7.4%	3.6%	-11.0%
WW	5,535	5,701	-2.9%	3.1%	-6.0%

<sup>(1)</sup> Operational growth excludes the effect of currency

<sup>(2)</sup> Select areas (unaudited)

<sup>(3)</sup> Prior year amounts have been reclassified to conform with current presentation

<sup>(4)</sup> For external purposes, reported as U.S. sales

<sup>(5)</sup> Included in Other

<sup>(6)</sup> Includes sales of Drug-Eluting Stents for Q1 2009 of \$68, \$184 and \$252 million Domestic, International and Worldwide respectively

Includes sales of Drug-Eluting Stents for Q1 2008 of \$169, \$231 and \$400 million Domestic, International and Worldwide respectively